Accredited Investors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.25M | Buy |
8,939
+728
| +9% | +$157K | 0.1% | 70 |
|
|
2026
Q1 | $1.79M | Sell |
8,211
-1,194
| -13% | -$265K | 0.1% | 73 |
|
|
2025
Q4 | $2.15M | Buy |
9,405
+399
| +4% | +$90.9K | 0.11% | 69 |
|
|
2025
Q3 | $2.09M | Buy |
9,006
+1,018
| +13% | +$207K | 0.12% | 66 |
|
|
2025
Q2 | $1.48M | Sell |
7,988
-70
| -0.9% | -$13K | 0.09% | 78 |
|
|
2025
Q1 | $1.69M | Sell |
8,058
-33
| -0.4% | -$6.42K | 0.1% | 67 |
|
|
2024
Q4 | $1.44M | Buy |
8,091
+159
| +2% | +$29.2K | 0.08% | 74 |
|
|
2024
Q3 | $1.57M | Buy |
7,932
+1,246
| +19% | +$233K | 0.09% | 74 |
|
|
2024
Q2 | $1.15M | Sell |
6,686
-96
| -1% | -$15.9K | 0.07% | 81 |
|
|
2024
Q1 | $1.23M | Sell |
6,782
-108
| -2% | -$18.6K | 0.08% | 82 |
|
|
2023
Q4 | $1.07M | Sell |
6,890
-309
| -4% | -$45K | 0.08% | 86 |
|
|
2023
Q3 | $1.07M | Buy |
7,199
+424
| +6% | +$62.2K | 0.08% | 79 |
|
|
2023
Q2 | $913K | Sell |
6,775
-228
| -3% | -$33.4K | 0.07% | 85 |
|
|
2023
Q1 | $1.12M | Sell |
7,003
-38
| -0.5% | -$5.81K | 0.08% | 73 |
|
|
2022
Q4 | $1.14M | Buy |
7,041
+644
| +10% | +$98.7K | 0.1% | 69 |
|
|
2022
Q3 | $859K | Buy |
6,397
+491
| +8% | +$70.5K | 0.1% | 73 |
|
|
2022
Q2 | $905K | Buy |
5,906
+56
| +1% | +$8.56K | 0.11% | 75 |
|
|
2022
Q1 | $948K | Buy |
5,850
+186
| +3% | +$27K | 0.09% | 78 |
|
|
2021
Q4 | $767K | Sell |
5,664
-642
| -10% | -$75.8K | 0.07% | 91 |
|
|
2021
Q3 | $680K | Buy |
6,306
+392
| +7% | +$44.8K | 0.07% | 87 |
|
|
2021
Q2 | $666K | Buy |
5,914
+19
| +0.3% | +$2.14K | 0.07% | 87 |
|
|
2021
Q1 | $638K | Sell |
5,895
-131
| -2% | -$14K | 0.09% | 84 |
|
|
2020
Q4 | $646K | Buy |
6,026
+37
| +0.6% | +$3.56K | 0.11% | 81 |
|
|
2020
Q3 | $525K | Hold |
5,989
| – | – | 0.11% | 82 |
|
|
2020
Q2 | $588K | Buy |
5,989
+21
| +0.4% | +$1.85K | 0.12% | 78 |
|
|
2020
Q1 | $455K | Buy |
5,968
+44
| +0.7% | +$3.75K | 0.11% | 83 |
|
|
2019
Q4 | $525K | Buy |
5,924
+170
| +3% | +$14.1K | 0.09% | 86 |
|
|
2019
Q3 | $436K | Sell |
5,754
-475
| -8% | -$32.6K | 0.08% | 84 |
|
|
2019
Q2 | $453K | Buy |
6,229
+21
| +0.3% | +$1.65K | 0.09% | 85 |
|
|
2019
Q1 | $500K | Buy |
6,208
+537
| +9% | +$43.9K | 0.1% | 82 |
|
|
2018
Q4 | $523K | Buy |
5,671
+1,625
| +40% | +$143K | 0.12% | 71 |
|
|
2018
Q3 | $383K | Buy |
4,046
+361
| +10% | +$34.2K | 0.09% | 80 |
|
|
2018
Q2 | $341K | Buy |
3,685
+87
| +2% | +$8.5K | 0.09% | 80 |
|
|
2018
Q1 | $341K | Buy |
3,598
+5
| +0.1% | +$549 | 0.09% | 76 |
|
|
2017
Q4 | $348K | Buy |
3,593
+720
| +25% | +$67.9K | 0.1% | 79 |
|
|
2017
Q3 | $255K | Buy |
+2,873
| New | +$219K | 0.07% | 96 |
|
|
2017
Q2 | – | Sell |
-5,066
| Closed | -$330K | – | 107 |
|
|
2017
Q1 | $330K | Sell |
5,066
-389
| -7% | -$24.5K | 0.08% | 76 |
|
|
2016
Q4 | $342K | Buy |
5,455
+388
| +8% | +$23.7K | 0.09% | 69 |
|
|
2016
Q3 | $320K | Sell |
5,067
-52
| -1% | -$3.37K | 0.09% | 73 |
|
|
2016
Q2 | $264K | Buy |
5,119
+852
| +20% | +$51.9K | 0.07% | 77 |
|
|
2016
Q1 | $244K | Hold |
4,267
| – | – | 0.06% | 79 |
|
|
2015
Q4 | $253K | Hold |
4,267
| – | – | 0.06% | 78 |
|
|
2015
Q3 | $233K | Hold |
4,267
| – | – | 0.06% | 74 |
|
|
2015
Q2 | $287K | Buy |
4,267
+200
| +5% | +$13.1K | 0.08% | 59 |
|
|
2015
Q1 | $239K | Sell |
4,067
-94
| -2% | -$5.68K | 0.06% | 63 |
|
|
2014
Q4 | $273K | Buy |
4,161
+58
| +1% | +$3.66K | 0.08% | 60 |
|
|
2014
Q3 | $235K | Sell |
4,103
-220
| -5% | -$12.2K | 0.07% | 63 |
|
|
2014
Q2 | $244K | Hold |
4,323
| – | – | 0.08% | 59 |
|
|
2014
Q1 | $223K | Buy |
+4,323
| New | +$218K | 0.07% | 57 |
|
Other funds holding ABBV
Accredited Investors's ABBV Position: Q2 2026 in Review
Accredited Investors increased its AbbVie (ABBV) stake by 8.9% in Q2 2026, buying an estimated $157K and bringing the position to 8,939 shares worth $2.25M. The position accounts for 0.1% of the portfolio, ranked #70.
Accredited Investors first reported a position in ABBV in Q1 2014 and has held it in 49 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Accredited Investors held 8,939 shares of AbbVie worth $2.25M as of Q2 2026.
- Accredited Investors bought 728 AbbVie shares in Q2 2026, an estimated $157K.
- AbbVie made up 0.1% of Accredited Investors's portfolio in Q2 2026, its #70 holding.
- Accredited Investors first reported a position in AbbVie in Q1 2014 and has held it in 49 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Accredited Investors's 13F filing for Q2 2026, filed 21 Jul 2026.